Management of Candida Infections of the Urinary System
Current Fungal Infection Reports · 2026-12 · 20 (1)
DOI: 10.1007/s12281-026-00527-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Fungal Infection Reports, online erschienen am 21.04.2026. Verfasst von Adam G. Stewart und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
To provide a concise, practice-oriented synthesis on Candida urinary tract infections: epidemiology and clinical significance of candiduria; when candiduria reflects colonization vs. infection; pharmacology of key antifungals focused on urinary and renal tissue penetration; the roles of source control and urologic intervention; and management in special scenarios (pre-urologic procedures, obstruction, devices, and impaired renal function). Fluconazole remains first-line therapy for susceptible isolates given excellent urinary and renal penetration. Echinocandins and lipid amphotericin B achieve low urinary concentrations and may be unreliable for treatment of cystitis, whereas amphotericin B deoxycholate and flucytosine attain therapeutic urinary concentrations (with nephrotoxicity and hematologic toxicity considerations). Novel agents such as rezafungin, fosmanogepix, oteseconazole, ibrexafungerp and encochleated amphotericin B show promising PK/tissue distribution but there are limited data defining their potential role in treating lower-tract disease. Intravesical or nephrostomy instillation of amphotericin B can produce short-term clearance in resistant or device-associated infections, yet relapse is common without addressing obstruction or removing/exchanging hardware. Pre-procedural candiduria may increase postoperative complications in selected populations; short-course targeted therapy is reasonable before intermediate-/high-risk genitourinary interventions. Renal impairment requires dose adjustment for fluconazole and flucytosine, avoidance of cyclodextrin-containing IV azoles, and preference for lipid amphotericin when a polyene is needed. The work up of candiduria should prioritize confirming infection, prompt source control (catheter/device management, relief of obstruction), and organism-directed therapy. Treat selectively: many asymptomatic cases resolve with device measures alone; symptomatic or high-risk situations are best treated with fluconazole when active, or amphotericin B deoxycholate or flucytosine for resistant species. Reserve local instillation for carefully chosen cases. Coordinated ID–urology care and procedure-specific planning reduce relapse and complications; key gaps include standardized instillation regimens and trials defining who benefits from antifungal therapy and the role of novel antifungals.
Zitieren
APA
Stewart, A. G., & Hammond, S. P. (2026). Management of Candida Infections of the Urinary System. Current Fungal Infection Reports, 20(1). https://doi.org/10.1007/s12281-026-00527-0
Vancouver
Stewart AG, Hammond SP. Management of Candida Infections of the Urinary System. Current Fungal Infection Reports. 2026;20(1). doi:10.1007/s12281-026-00527-0
BibTeX
@article{Stewart2026,
author = {Stewart, Adam G. and Hammond, Sarah P.},
title = {Management of Candida Infections of the Urinary System},
journal = {Current Fungal Infection Reports},
year = {2026},
volume = {20},
number = {1},
doi = {10.1007/s12281-026-00527-0}
}
EUVIMED